Clinical Trials · NCT00414973

A Study for Patients With Osteoporosis

CompletedPhase 3Teriparatide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
364
Start date
Dec 2006
Locations
5 sites, China
Primary endpoint
Percentage Change From Baseline to 24 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD), Postmenopausal Women
View Teriparatide compound reference